The same group conducted another clinical trial involving MM patients who received an anti-programmed cell death protein 1 (PD-1) antibody (Pidilizumab) in combination with a DC/myeloma fusion cell vaccine following autologous transplantation with the aim to overcome the immunosuppressive milieu by which tumor cells evade host immunity. The gene discussed is PDCD1; the disease is neoplasm.